BiotechTV - News

CEO Hugo Fry describes the scientific idea behind antigenic tolerization, and discusses Topas' recent PoC data that was presented at Digestive Disease Week.

He explains the story of this enzyme and the biology of how CTPS1 and CTPS2 interact. Step is in the clinic in lymphoma and solid tumors, and recently raised a €38 series C.

CEO Jordi Fàbrega and CFO Josep Prous discusses the asset, CTH120, which is a NCE and proprietary to Connecta.

CEO Jean Marie Duvall describes the company's programs, one focused on male inferitliy and another that may have dual purposes of helping with embryo implantation and adenomyosis. She says to make sure there is a clear commercial path if when you focus on this field.

CEO Birgit Zech and CSO Edward Holson discuss the unique beginning of the company (a powerpoint deck), and the difficulties in drugging phosphatases. Plus, the company is now disclosing two indications/targets in development.

CEO Antti Vuolanto walks us through recent phase 1b data, which reported safety and PK data. Biomarker data will be forthcoming before the end of the year.

Valneva CEO Thomas Lingelbach walks us through this program by describing how the vaccine is designed and how the study has been conducted. Plus, his comments on FDA's rescinding of the company's Chikungunya virus vaccine.

Manifold Co-Founders Gleb Kuznetsov and Pierce Ogden explain how Manifold is working on next generation shuttles, which means going beyond transferrin. They discuss the deal, and also Manifold's broader platform of high-throughput, in-vivo discovery work.

He describes the unmet need for a better vaccine than those already on the market, and says he is looking for a lead investor for a series A at BIO-Europe.

He describes the mechanism of the therapy, as well the data and commercial landscape for UC. Plus, how he thinks about combos and business development.

CEO Natalia Misciattelli describes the lead programs for Stargardt Disease and Usher 1B Syndrome, and how AAVantgarde is able to solve the problem of delivering genes that are naturally too large for single AAV vectors.

He explains the company's "Helicon" peptide platform, and why he believes it is well suited to target previously undruggable problems like beta-catenin. Then he discusses clinical presentations on this program in multiple tumor types, and preclinical data on two degrader programs for prostate cancer.

Co-Founder and CEO Ron Alfa walked BiotechTV's Ryan Flinn through how machine learning is taking cancer cell biology beyond the microscope.

They explain why they believe a Treg based cell therapy is the right approach for autoimmune conditions, and describe the construct of this particular product. After discussing the data, they also comment on what they believe the big picture is for these types of Treg based treatments going forward.

CEO Jason Cole walks us through this unique science, which is based on work that co-founder Diane Mathis and colleagues published in Cell in 2022. The T1D program is scheduled to be in the clinic by late 2026.

The company's lead program, a bi-specific called Sutacimig, has already reported phase 2 data for Glanzmann Thrombasthenia, and will start a pivotal in 2026. Hemab also has a monovalent antibody (HMB-022) in the clinic for the world's most common bleeding disorder, Von Willebrand Disease, and will be announcing an additional candidate next year.

Co-Founder & CEO Brandon Rice says that in one project it worked on with a pharma, Weave's technology took only 3 hours to draft regulatory documents what would have taken humans to 100 hours.

He walks us through exon 44 and 45 programs, which will both likely have clinical readouts in 2026. Meanwhile, a $350M cash position gives Entrada the ability to think beyond neuromuscular conditions in the future as well.

He describes how Disc applied for and was awarded a CNPV for Bitopertin, which treats a rare disease that causes extreme sensitivity to sunlight. Plus, quickly ramping up a commercial team, and discussing Disc's two other development programs.

MassBio CEO Kendalle Burlin O'Connell moderates a discussion with Normunity CEO Rachel Humphrey and Gallop Oncology CEO Luba Greenwood about how they are rising to today's challenges. Topics include the funding environment, motivating your team, storytelling, FDA Engagement, and perseverance.

Co-Founder and CEO Molly Gibson explains the science behind the new company and the technology and equipment it uses for the work. Expedition has been funded with $50 million, and is also announcing a multi-target deal with Pfizer for prostate cancer.

He describes CUE-401, which combines a TGF-beta breathing-mask moiety with an interleukin (IL-2) mutein, and CUE-501, a Boehringer Ingelheim partnered program which is designed to deplete B-cells by painting them and engaging with virus-specific memory T-cells.

During a meeting in Boston at Portal Innovations where Women in Bio (WIB) was working on its 'Boardroom Ready' initiative, Dianne Keen-Kim (National President and Board Chair), Gina Ford (CEO), and Katherine Andersen (Board Member) discuss how WIB helps women in our industry today and its goals for the future.

Chairman & CEO Ben Hwang describes the idea behind Profusa's approach, and how he believes it delivers more robust and actionable information than purely surface based tools such as the Apple Watch.

He describes the science behind PepGen's "Enhanced Delivery Oligonucleotide (EDO)" platform, and explain how he believes it gives the company a differentiated advantage in this condition by focusing on the pathogenic repeat that causes DM1 and restoring normal function.